Drug Trial Radar · NCT07073417
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
163
Actual
Start
Jul 28, 2025
Primary completion
Feb 27, 2027
Study completion Aug 23, 2027
Sponsor
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
Conditions
- Obesity
- Weight Management
Interventions
XW003 injectionDrug
Subcutaneous injection
semaglutide injectionDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight relative to baselineTime frame: week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.